Pancreatic Cancer Research

ResearcherShiga University of Medical ScienceActive in the last 2 years

Atsuhiro Masuda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2138-1207; OpenAlex author ID A5055932971. Sources: OpenAlex.

Their work

Papers
27 (first author 12, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
96
Papers, trials and grants by year

2017: 1 paper · 2018: 3 papers · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 6 papers · 2024: 6 papers · 2025: 1 paper · 2026: 6 papers

Papers 27

  1. Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer. Co-author DOI 10.1007/s00535-025-02321-0↗
  2. Spatial Profiling Identified Senescent Cancer-Associated Fibroblasts Localized in the Border Region of Human Pancreatic Ductal Adenocarcinoma. First author DOI 10.1016/j.jcmgh.2026.101808↗
  3. Biological Borderline Resectable Pancreatic Cancer Represents a Genetically and Immunologically Aggressive Subtype: A Retrospective Study. First author DOI 10.1097/sla.0000000000007075↗
  4. Impact of Stent Type on Surgical Outcomes in Pancreatic Cancer Patients Undergoing Preoperative Biliary Drainage. Co-author DOI 10.1111/den.70229↗
  5. Deep Learning Detection of Direct and Indirect Imaging Findings Associated with Pancreatic Cancer at Contrast-enhanced and Noncontrast CT. Co-author DOI 10.1148/radiol.253122↗
  6. Early detection of pancreatic ductal adenocarcinoma by single-molecule profiling of pancreatic enzyme activities Co-author DOI 10.64898/2026.06.05.730533↗
  7. Multicenter Comparative Study of 6- and 10-mm Fully Covered Self-Expandable Metal Stents for Malignant Distal Biliary Obstruction During Neoadjuvant Chemothera… First author DOI 10.1002/jhbp.12157↗
  8. Temporal progression of pancreatic cancer computed tomography findings until diagnosis: A large-scale multicenter study. First author DOI 10.1002/ueg2.12557↗
  9. Impact of intratumoral microbiome on tumor immunity and prognosis in human pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00535-023-02069-5↗
  10. Association of pancreatic atrophy patterns with intraductal extension of early pancreatic ductal adenocarcinoma: a multicenter retrospective study. First author DOI 10.1007/s00535-024-02149-0↗
  11. Role of Wnt5b-Ror1 signaling in the proliferation of pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1111/gtc.13115↗
  12. Rim Enhancement on Contrast-Enhanced CT as a Predictor of Prognosis in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/diagnostics14080782↗
  13. Treatment and Prognosis for Pancreatic Duct Disruption Associated With Pancreatic Cancer: A Case Series of 15 Patients. Co-author DOI 10.7759/cureus.67482↗
  14. Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00535-022-01939-8↗
  15. A comprehensive analysis of tumor-stromal collagen in relation to pathological, molecular, and immune characteristics and patient survival in pancreatic ductal… First author DOI 10.1007/s00535-023-02020-8↗
  16. A case of pancreatic ductal adenocarcinoma concomitant with IgG4-related disease in the pancreas and the stomach. Co-author DOI 10.1007/s12328-023-01814-w↗
  17. Benefits of pancreatic parenchymal endoscopic ultrasonography in predicting microscopic precancerous lesions of pancreatic cancer. Co-author DOI 10.1038/s41598-023-38920-1↗
  18. Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Ductal Adenocarcinoma: A Retrospective Anal… Co-author DOI 10.1245/s10434-023-13569-2↗
  19. ASO Author Reflections: Relationship Between Sarcopenia, Patient Prognosis, and Tumor-Infiltrating T Cells in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-023-13575-4↗
  20. Comprehensive Analysis of Molecular Biologic Characteristics of Pancreatic Ductal Adenocarcinoma Concomitant with Intraductal Papillary Mucinous Neoplasm. First author DOI 10.1245/s10434-022-11704-z↗
  21. Increased expression of SPRR1A is associated with a poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0266620↗
  22. Prospective Study Using Plasma Apolipoprotein A2-Isoforms to Screen for High-Risk Status of Pancreatic Cancer. Co-author DOI 10.3390/cancers12092625↗
  23. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1038/s41436-018-0009-5↗
  24. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2017.3420↗
  25. Pancreatic inflammation and atrophy are not associated with pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. First author DOI 10.1016/j.pan.2017.12.007↗
  26. Multifocal cysts and incidence of pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. First author DOI 10.1016/j.pan.2018.04.005↗
  27. Smoking Status and the Incidence of Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm. First author DOI 10.1097/mpa.0000000000000761↗

Closest collaborators

The 25 strongest of 96 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Arata Sakai · 15 shared papers, 2018–2026 · strength 2.22
  2. Yuzo Kodama · 14 shared papers, 2020–2025 · strength 2.13
  3. Hirochika Toyama · 15 shared papers, 2017–2024 · strength 1.96
  4. Takashi Kobayashi · 15 shared papers, 2017–2026 · strength 1.89
  5. Keitaro Sofue · 13 shared papers, 2017–2026 · strength 1.71
  6. Masanori Gonda · 11 shared papers, 2022–2026 · strength 1.66
  7. Takumi Fukumoto · 13 shared papers, 2017–2026 · strength 1.66
  8. Kohei Yamakawa · 9 shared papers, 2022–2024 · strength 1.41
  9. Masahiro Tsujimae · 9 shared papers, 2022–2026 · strength 1.30
  10. Mika Miki · 8 shared papers, 2023–2026 · strength 1.26
  11. Yoshiyuki Harada · 7 shared papers, 2023–2026 · strength 1.20
  12. Shigeto Masuda · 7 shared papers, 2022–2024 · strength 1.07
  13. Shohei Abe · 7 shared papers, 2022–2024 · strength 0.94
  14. Takeshi Tanaka · 7 shared papers, 2022–2024 · strength 0.93
  15. Tomoo Itoh · 7 shared papers, 2022–2024 · strength 0.93
  16. Mamoru Takenaka · 7 shared papers, 2017–2026 · strength 0.93
  17. Shigeto Ashina · 6 shared papers, 2022–2026 · strength 0.81
  18. Ryota Nakano · 5 shared papers, 2022–2025 · strength 0.79
  19. Yuzo Kodama · 3 shared papers, 2026 · strength 0.72
  20. Takuya Ikegawa · 6 shared papers, 2018–2026 · strength 0.71
  21. Yoshihide Nanno · 3 shared papers, 2023–2026 · strength 0.63
  22. Tomonori Matsumoto · 2 shared papers, 2024–2026 · strength 0.45
  23. Takayuki Kodama · 2 shared papers, 2024–2026 · strength 0.40
  24. Takamichi Murakami · 2 shared papers, 2024–2026 · strength 0.39
  25. Takeru Yamaguchi · 2 shared papers, 2024–2026 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.